V
323990
vs
PNEXF
PNEXF
Over the past 12 months, Vaxcell Bio Therapeutics has outperformed PNEXF, delivering a return of +2% compared to the PNEXF's 0% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
PNEXF
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics
KOSDAQ:323990
|
9 490
KRW
|
|||||
|
Pharnext SCA
OTC:PNEXF
|
999 999.9999
USD
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
323990, PNEXF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
V
|
Vaxcell Bio Therapeutics
Revenue
|
|||||||||||
|
|
Pharnext SCA
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
323990, PNEXF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
V
|
Vaxcell Bio Therapeutics
KOSDAQ:323990
|
|||||||||
|
|
Pharnext SCA
OTC:PNEXF
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
ROA
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics | ||||
|
|
Pharnext SCA | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
323990, PNEXF
Performance Gap
323990, PNEXF
Performance By Year
323990, PNEXF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|
